Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 12
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Psatha, Nikoletta Karponi, Garyfalia and Yannaki, Evangelia 2016. Optimizing autologous cell grafts to improve stem cell gene therapy. Experimental Hematology, Vol. 44, Issue. 7, p. 528.

    Karponi, G. Psatha, N. Lederer, C. W. Adair, J. E. Zervou, F. Zogas, N. Kleanthous, M. Tsatalas, C. Anagnostopoulos, A. Sadelain, M. Riviere, I. Stamatoyannopoulos, G. and Yannaki, E. 2015. Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy. Blood, Vol. 126, Issue. 5, p. 616.

    Boulad, F. Wang, X. Qu, J. Taylor, C. Ferro, L. Karponi, G. Bartido, S. Giardina, P. Heller, G. Prockop, S. E. Maggio, A. Sadelain, M. and Riviere, I. 2014. Safe mobilization of CD34+ cells in adults with  -thalassemia and validation of effective globin gene transfer for clinical investigation. Blood, Vol. 123, Issue. 10, p. 1483.

    Finotti, Alessia and Gambari, Roberto 2014. Recent trends for novel options in experimental biological therapy of β-thalassemia. Expert Opinion on Biological Therapy, Vol. 14, Issue. 10, p. 1443.

    Vannocci, Tommaso Kurata, Hitoshi de la Fuente, Josu Roberts, Irene A. and Porter, Andrew C. G. 2014. Nuclease-stimulated homologous recombination at the human β-globin gene. The Journal of Gene Medicine, Vol. 16, Issue. 1-2, p. 1.

    Breda, Laura Rivella, Stefano Zuccato, Cristina and Gambari, Roberto 2013. Combining gene therapy and fetal hemoglobin induction for treatment of β-thalassemia. Expert Review of Hematology, Vol. 6, Issue. 3, p. 255.

    Lai, Wing-Fu 2013. Nucleic acid delivery: Roles in biogerontological interventions. Ageing Research Reviews, Vol. 12, Issue. 1, p. 310.

    Yannaki, Evangelia Karponi, Garyfalia Zervou, Fani Constantinou, Varnavas Bouinta, Asimina Tachynopoulou, Varvara Kotta, Konstantina Jonlin, Erica Papayannopoulou, Thalia Anagnostopoulos, Achilles and Stamatoyannopoulos, George 2013. Hematopoietic Stem Cell Mobilization for Gene Therapy: Superior Mobilization by the Combination of Granulocyte–Colony Stimulating Factor Plus Plerixafor in Patients with β-Thalassemia Major. Human Gene Therapy, Vol. 24, Issue. 10, p. 852.

    Gambari, Roberto 2012. Alternative options for DNA-based experimental therapy of β-thalassemia. Expert Opinion on Biological Therapy, Vol. 12, Issue. 4, p. 443.

    Higgs, Douglas R Engel, James Douglas and Stamatoyannopoulos, George 2012. Thalassaemia. The Lancet, Vol. 379, Issue. 9813, p. 373.

    Humbert, Olivier Davis, Luther and Maizels, Nancy 2012. Targeted gene therapies: tools, applications, optimization. Critical Reviews in Biochemistry and Molecular Biology, Vol. 47, Issue. 3, p. 264.

    Wu, Chuanfeng and Dunbar, Cynthia E. 2011. Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity. Frontiers of Medicine, Vol. 5, Issue. 4, p. 356.

  • Expert Reviews in Molecular Medicine, Volume 12
  • 2010, e31

Gene therapy for β-thalassaemia: the continuing challenge

  • Evangelia Yannaki (a1), David W. Emery (a2) (a3) and George Stamatoyannopoulos (a2) (a4)
  • DOI:
  • Published online: 01 October 2010

The β-thalassaemias are inherited anaemias that form the most common class of monogenic disorders in the world. Treatment options are limited, with allogeneic haematopoietic stem cell transplantation offering the only hope for lifelong cure. However, this option is not available for many patients as a result of either the lack of compatible donors or the increased risk of transplant-related mortality in subjects with organ damage resulting from accumulated iron. The paucity of alternative treatments for patients that fall into either of these categories has led to the development of a revolutionary treatment strategy based on gene therapy. This approach involves replacing allogeneic stem cell transplantation with the transfer of normal globin genes into patient-derived, autologous haematopoietic stem cells. This highly attractive strategy offers several advantages, including bypassing the need for allogeneic donors and the immunosuppression required to achieve engraftment of the transplanted cells and to eliminate the risk of donor-related graft-versus-host disease. This review discusses the many advances that have been made towards this endeavour as well as the hurdles that must still be overcome before gene therapy for β-thalassaemia, as well as many other gene therapy applications, can be widely applied in the clinic.

Corresponding author
*Corresponding author: Evangelia Yannaki, G. Papanicolaou Hospital, Gene and Cell Therapy Center, Hematology-BMT Unit, Thessaloniki 57010, Greece. E-mail:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

3G. Lucarelli , M. Andreani and E. Angelucci (2002) The cure of thalassemia by bone marrow transplantation. Blood Reviews 16, 81-85

4D. Gaziev (1997) Graft-versus-host disease after bone marrow transplantation for thalassemia: an analysis of incidence and risk factors. Transplantation 63, 854-860

7G. La Nasa (2005) Unrelated donor stem cell transplantation in adult patients with thalassemia. Bone Marrow Transplantation 36, 971-975

8D. Gaziev (2000) Bone marrow transplantation from alternative donors for thalassemia: HLA-phenotypically identical relative and HLA-nonidentical sibling or parent transplants. Bone Marrow Transplantation 25, 815-821

9G. Lucarelli and J. Gaziev (2008) Advances in the allogeneic transplantation for thalassemia. Blood Reviews 22, 53-63

10L. Lisowski and M. Sadelain (2008) Current status of globin gene therapy for the treatment of beta-thalassaemia. British Journal of Haematology 141, 335-345

11D.W. Emery (2002) Hematopoietic stem cell gene therapy. International Journal of Hematology 75, 228-236

12D.B. Kohn (2003) American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Molecular Therapy 8, 180-187

13C. Berry (2006) Selection of target sites for mobile DNA integration in the human genome. PLoS Computation Biology 2, e157

14D.W. Emery , M. Aker and G. Stamatoyannopoulos (2003) Chromatin insulators and position effects. In Gene Transfer and Expression in Mammalian Cells (S.C. Makrides , ed.), pp. 381-395, EIC Laboratories, Inc., Norwood, MA, USA

15Q. Li (2002) Locus control regions. Blood 100, 3077-3086

16F. Grosveld (1987) Position-independent, high-level expression of the human beta-globin gene in transgenic mice. Cell 51, 975-985

17G. Blom van Assendelft (1989) The beta-globin dominant control region activates homologous and heterologous promoters in a tissue-specific manner. Cell 56, 969-977

18S. Karlsson (1987) Retroviral-mediated transfer of genomic globin genes leads to regulated production of RNA and protein. Proceedings of the National Academy of Sciences of the United States of America 84, 2411-2415

19E.A. Dzierzak , T. Papayannopoulou and R.C. Mulligan (1988) Lineage-specific expression of a human beta-globin gene in murine bone marrow transplant recipients reconstituted with retrovirus-transduced stem cells. Nature 331, 35-41

21U. Novak (1990) High-level beta-globin expression after retroviral transfer of locus activation region-containing human beta-globin gene derivatives into murine erythroleukemia cells. Proceedings of the National Academy of Sciences of the United States of America 87, 3386-3390

22D.W. Emery (1998) Development of a condensed locus control region cassette and testing in retrovirus vectors for A gamma-globin. Blood Cells, Molecules, and Diseases 24, 322-339

23M. Sadelain (1995) Generation of a high-titer retroviral vector capable of expressing high levels of the human beta-globin gene. Proceedings of the National Academy of Sciences of the United States of America 92, 6728-6732

26D.W. Emery (2002) Development of virus vectors for gene therapy of beta chain hemoglobinopathies: flanking with a chromatin insulator reduces gamma-globin gene silencing in vivo. Blood 100, 2012-2019

27H. Miyoshi (1999) Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 283, 682-686

28M. Kumar (2001) Systematic determination of the packaging limit of lentiviral vectors. Human Gene Therapy 12, 1893-1905

33L. Naldini and I.M. Verma (2000) Lentiviral vectors. Advances in Virus Research 55, 599-609

34M.A. Kay , J.C. Glorioso and L. Naldini (2001) Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nature Medicine 7, 33-40

35E. Montini (2006) Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nature Biotechnology 24, 687-696

36P.I. Arumugam (2009) Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region. Molecular Therapy 17, 1929-1937

37R. Pawliuk (2001) Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 294, 2368-2371

38S. Imren (2002) Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells. Proceedings of the National Academy of Sciences of the United States of America 99, 14380-14385

39D.A. Persons (2003) The degree of phenotypic correction of murine beta -thalassemia intermedia following lentiviral-mediated transfer of a human gamma-globin gene is influenced by chromosomal position effects and vector copy number. Blood 101, 2175-2183

40S. Rivella (2003) A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. Blood 101, 2932-2939

41A. Miccio (2008) In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia. Proceedings of the National Academy of Sciences of the United States of America 105, 10547-10552

42A. Perumbeti (2009) A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction. Blood 114, 1174-1185

43G. Puthenveetil (2004) Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector. Blood 104, 3445-3453

44M. Aker (2007) Extended core sequences from the cHS4 insulator are necessary for protecting retroviral vectors from silencing position effects. Human Gene Therapy 18, 333-343

45P.I. Arumugam (2007) Improved human beta-globin expression from self-inactivating lentiviral vectors carrying the chicken hypersensitive site-4 (cHS4) insulator element. Molecular Therapy 15, 1863-1871

46C. May (2002) Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene. Blood 99, 1902-1908

47M. Cavazzana-Calvo (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288, 669-672

48S. Hacein-Bey-Abina (2002) Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. New England Journal of Medicine 346, 1185-1193

49H.B. Gaspar (2004) Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364, 2181-2187

50A. Aiuti (2009) Gene therapy for immunodeficiency due to adenosine deaminase deficiency. New England Journal of Medicine 360, 447-458

51S. Hacein-Bey-Abina (2008) Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. Journal of Clinical Investigation 118, 3132-3142

52S.J. Howe (2008) Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. Journal of Clinical Investigation 118, 3143-3150

53S. Hacein-Bey-Abina (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415-419

54M.G. Ott (2006) Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nature Medicine 12, 401-409

55S. Stein (2010) Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nature Medicine 16, 198-204

56A. Aiuti (2007) Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. Journal of Clinical Investigation 117, 2233-2240

57Z. Li (2002) Murine leukemia induced by retroviral gene marking. Science 296, 497

58Y. Shou (2006) Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proceedings of the National Academy of Sciences of the United States of America 103, 11730-11735

59O. Kustikova (2005) Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 308, 1171-1174

60C.L. Li (2009) Genomic and functional assays demonstrate reduced gammaretroviral vector genotoxicity associated with use of the cHS4 chromatin insulator. Molecular Therapy 17, 716-724

61R. Seggewiss (2006) Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque. Blood 107, 3865-3867

62M. Sadelain (2004) Insertional oncogenesis in gene therapy: how much of a risk? Gene Therapy 11, 569-573

63C. Baum (2002) Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 101, 2099-2114

64M. Aker (2006) Integration bias of gammaretrovirus vectors following transduction and growth of primary mouse hematopoietic progenitor cells with and without selection. Molecular Therapy 14, 226-235

65E.M. Poeschla (2008) Integrase, LEDGF/p75 and HIV replication. Cellular and Molecular Life Sciences 65, 1403-1424

66E. Montini (2009) The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. Journal of Clinical Investigation 119, 964-975

67A.R. Schroder (2002) HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110, 521-529

68W. Wu (2003) Transcription start regions in the human genome are favored targets for MLV integration. Science 300, 1749-1751

69D. Zychlinski (2008) Physiological promoters reduce the genotoxic risk of integrating gene vectors. Molecular Therapy 16, 718-725

70A.H. Chang and M. Sadelain (2007) The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the LTR, and the promise of lineage-restricted vectors. Molecular Therapy 15, 445-456

71P.W. Hargrove (2008) Globin lentiviral vector insertions can perturb the expression of endogenous genes in beta-thalassemic hematopoietic cells. Molecular Therapy 16, 525-533

72M. Gaszner and G. Felsenfeld (2006) Insulators: exploiting transcriptional and epigenetic mechanisms. Nature Reviews Genetics 7, 703-713

73J.A. Wallace and G. Felsenfeld (2007) We gather together: insulators and genome organization. Current Opinion in Genetics and Development 17, 400-407

74J.H. Chung , A.C. Bell and G. Felsenfeld (1997) Characterization of the chicken beta-globin insulator. Proceedings of the National Academy of Sciences of the United States of America 94, 575-580

75S. Rivella (2000) The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites. Journal of Virology 74, 4679-4687

76D.W. Emery (2000) A chromatin insulator protects retrovirus vectors from chromosomal position effects. Proceedings of the National Academy of Sciences of the United States of America 97, 9150-9155

77E. Yannaki (2002) Topological constraints governing the use of the chicken HS4 chromatin insulator in oncoretrovirus vectors. Molecular Therapy 5, 589-598

79A. Ramezani , T.S. Hawley and R.G. Hawley (2008) Combinatorial incorporation of enhancer-blocking components of the chicken beta-globin 5′HS4 and human T-cell receptor alpha/delta BEAD-1 insulators in self-inactivating retroviral vectors reduces their genotoxic potential. Stem Cells 26, 3257-3266

80T. Nishino (2006) Effects of human gamma-globin in murine beta-thalassaemia. British Journal of Haematology 134, 100-108

81T. Neff (2003) Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model. Journal of Clinical Investigation 112, 1581-1588

84D.W. Emery (2005) Selection with a regulated cell growth switch increases the likelihood of expression for a linked gamma-globin gene. Blood Cells, Molecules, and Diseases 34, 235-247

85H. Zhao (2009) Amelioration of murine beta-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both gamma-globin and the MGMT drug-resistance gene. Blood 113, 5747-5756

86L. Burroughs and R. Storb (2005) Low-intensity allogeneic hematopoietic stem cell transplantation for myeloid malignancies: separating graft-versus-leukemia effects from graft-versus-host disease. Current Opinion in Hematology 12, 45-54

87A. Aiuti (2002) Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296, 2410-2413

90C. Bordignon (1995) Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 270, 470-475

91D.B. Kohn (1995) Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nature Medicine 1, 1017-1023

92H.L. Malech (1997) Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proceedings of the National Academy of Sciences of the United States of America 94, 12133-12138

93D.B. Kohn (1998) T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nature Medicine 4, 775-780

94C.E. Dunbar (1998) Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation. Human Gene Therapy 9, 2629-2640

95F. Schuening (1997) Retrovirus-mediated transfer of the cDNA for human glucocerebrosidase into peripheral blood repopulating cells of patients with Gaucher's disease. Human Gene Therapy 8, 2143-2160

96P. Kelly (2007) Stem cell collection and gene transfer in Fanconi anemia. Molecular Therapy 15, 211-219

97E.M. Kang (2010) Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. Blood 115, 783-791

98H.B. Gaspar (2006) Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Molecular Therapy 14, 505-513

99N. Cartier (2009) Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326, 818-823

100A. Bank , R. Dorazio and P. Leboulch (2005) A phase I/II clinical trial of beta-globin gene therapy for beta-thalassemia. Annals of the New York Academy of Sciences, 1054, 308-316

101J. Kaiser (2010) Gene therapy. Beta-thalassemia treatment succeeds, with a caveat. Science 326, 1468-1469

103R. Iannone (2003) Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biology of Blood and Marrow Transplantation 9, 519-528

104D.A. Persons (2001) Functional requirements for phenotypic correction of murine beta-thalassemia: implications for human gene therapy. Blood 97, 3275-3282

105A. Gratwohl (2006) EBMT activity survey 2004 and changes in disease indication over the past 15 years. Bone Marrow Transplantation 37, 1069-1085

107C.E. Dunbar (1996) Improved retroviral gene transfer into murine and Rhesus peripheral blood or bone marrow repopulating cells primed in vivo with stem cell factor and granulocyte colony-stimulating factor. Proceedings of the National Academy of Sciences of the United States of America 93, 11871-11876

108P.A. Horn (2004) Efficient lentiviral gene transfer to canine repopulating cells using an overnight transduction protocol. Blood 103, 3710-3716

109B. Thomasson (2003) Direct comparison of steady-state marrow, primed marrow, and mobilized peripheral blood for transduction of hematopoietic stem cells in dogs. Human Gene Therapy 14, 1683-1686

110P. Hematti (2003) Retroviral transduction efficiency of G-CSF + SCF-mobilized peripheral blood CD34+ cells is superior to G-CSF or G-CSF + Flt3-L-mobilized cells in nonhuman primates. Blood 101, 2199-2205

111P. Hematti (2004) Comparison of retroviral transduction efficiency in CD34+ cells derived from bone marrow versus G-CSF-mobilized or G-CSF plus stem cell factor-mobilized peripheral blood in nonhuman primates. Stem Cells 22, 1062-1069

113D.P. O'Malley , M. Whalen and P.M. Banks (2003) Spontaneous splenic rupture with fatal outcome following G-CSF administration for myelodysplastic syndrome. American Journal of Hematology 73, 294-295

116M. Abboud , J. Laver and C.A. Blau (1998) Granulocytosis causing sickle-cell crisis. Lancet 351, 959

117B.K. Adler (2001) Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood 97, 3313-3314

118H.E. Broxmeyer (2005) Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. Journal of Experimental Medicine 201, 1307-1318

119A. Larochelle (2006) AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood 107, 3772-3778

120K. Li (1999) Granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in beta-thalassemia patients: kinetics of mobilization and composition of apheresis product. Experimental Hematology 27, 526-532

121E. Yannaki (2010) Mobilization of hematopoietic stem cells in a thalassemic mouse model: implications for human gene therapy of thalassemia. Human Gene Therapy 21, 299-310

122E. Yannaki and G. Stamatoyannopoulos (2010) Hematopoietic stem cell mobilization strategies for gene therapy of beta thalassemia and sickle cell disease. Annals of the New York Academy of Sciences 1202, 59-63

123M. Sadelain (2007) Therapeutic options for patients with severe beta-thalassemia: the need for globin gene therapy. Human Gene Therapy 18, 1-9

125V.K. Pathak and H.M. Temin (1990) Broad spectrum of in vivo forward mutations, hypermutations, and mutational hotspots in a retroviral shuttle vector after a single replication cycle: deletions and deletions with insertions. Proceedings of the National Academy of Sciences of the United States of America 87, 6024-6028

126M. Patel and S. Yang (2010) Advances in reprogramming somatic cells to induced pluripotent stem cells. Stem Cell Reviews 6, 367-380

128K. Takahashi and S. Yamanaka (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676

129J. Yu (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917-1920

130J. Yu (2009) Human induced pluripotent stem cells free of vector and transgene sequences. Science 324, 797-801

131D. Kim (2009) Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cells 4, 472-476

132A.D. Ebert (2009) Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 457, 277-280

133G. Lee (2009) Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 461, 402-406

134E. Kiskinis and K. Eggan (2010) Progress toward the clinical application of patient-specific pluripotent stem cells. Journal of Clinical Investigation 120, 51-59

135I. Park (2008) Disease-specific induced pluripotent stem cells. Cell 134, 877-886

136J. Hanna (2007) Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 318, 1920-1923

138L. Ye (2009) Induced pluripotent stem cells offer new approach to therapy in thalassemia and sickle cell anemia and option in prenatal diagnosis in genetic diseases. Proceedings of the National Academy of Sciences of the United States of America 106, 9826-9830

139K. Okita and S. Yamanaka (2010) Induction of pluripotency by defined factors. Experimental Cell Research 316, 2565-2570

140S. Yamanaka and H.M. Blau (2010) Nuclear reprogramming to a pluripotent state by three approaches. Nature 465, 704-712

142H.B. Gaspar (2009) How I treat ADA deficiency. Blood 114, 3524-3532

D.J. Weatherall (2010) The inherited diseases of hemoglobin are an emerging global health burden. Blood 115, 4331-4336

M. Sadelain (2008) Stem cell engineering for the treatment of severe hemoglobinopathies. Current Molecular Medicine 8, 690-697

F. Urbinati , C. Madigan and P. Malik (2006) Pathophysiology and therapy of haemoglobinopathies. Part II: thalassaemias. Expert Reviews in Molecular Medicine 8, 1-26

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *